Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders
- 27 March 2017
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (16) , E3243-E3250
Abstract
Rett syndrome (RTT) is an X-linked neurological disorder caused by mutations in the methyl-CpG–binding protein 2 (MeCP2) gene. The majority of RTT missense mutations disrupt the interaction of the MeCP2 with DNA or the nuclear receptor corepressor (NCoR)/silencing mediator of retinoic acid and thyroid receptors (SMRT) corepressor complex. Here, we show that the “NCoR/SMRT interaction domain” (NID) of MeCP2 directly contacts transducin beta-like 1 (TBL1) and TBL1 related (TBLR1), two paralogs that are core components of NCoR/SMRT. We determine the cocrystal structure of the MeCP2 NID in complex with the WD40 domain of TBLR1 and confirm by in vitro and ex vivo assays that mutation of interacting residues of TBLR1 and TBL1 disrupts binding to MeCP2. Strikingly, the four MeCP2-NID residues mutated in RTT are those residues that make the most extensive contacts with TBLR1. Moreover, missense mutations in the gene for TBLR1 that are associated with intellectual disability also prevent MeCP2 binding. Our study therefore reveals the molecular basis of an interaction that is crucial for optimal brain function. Significance Methyl-CpG–binding protein 2 (MeCP2) links epigenetics, brain function, and neurological disease. Mutations in the MeCP2 protein cause Rett syndrome (RTT), making it imperative to determine its mechanism of action. One domain of MeCP2 targets it to methylated DNA, but little was known about a second essential domain except that it recruits a gene-silencing complex. We determined that transducin beta-like (TBL) subunits of the silencing complex bind MeCP2 and solved the structure of the binary complex. Strikingly, amino acids mutated in RTT are precisely those amino acids that intimately contact the TBL subunits. Furthermore, mutations in TBL proteins that cause intellectual disability block interaction with MeCP2. Our data suggest that the TBL–MeCP2 interaction is essential for brain function.Keywords
Funding Information
- Wellcome Trust (091580)
- Wellcome Trust (107930)
- Wellcome Trust (092076)
- Wellcome Trust (095822)
- Wellcome Trust (108504)
- Medical Research Council (G1000520/1)
- Rett Syndrome Research Trust (4951)
This publication has 41 references indexed in Scilit:
- Methylation-Dependent and -Independent Genomic Targeting Principles of the MBD Protein FamilyCell, 2013
- Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responsesNature Neuroscience, 2011
- Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machineryNature Structural & Molecular Biology, 2011
- Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)Proceedings of the National Academy of Sciences, 2010
- DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl ResourcesThe American Journal of Human Genetics, 2009
- Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndromeAnnals of Neurology, 2009
- MeCP2 Binding to DNA Depends upon Hydration at Methyl-CpGMolecular Cell, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNACell, 1992